Academics argue that regulations are obstructing Canadian cannabis research

Academics affiliated with the University of Toronto are calling out the “purgatory” surrounding clinical cannabis research in Canada. In an article published in The Lancet, a peer-reviewed medical journal, the authors write that three years into legalization, it is still “impossible to conduct high-quality research, independent from industry” due to federal regulations. 

Unlike alcohol and tobacco research, which is conducted independently from those industries, cannabis research is reliant on cooperation from industry partners.

In particular, the authors note that the current regulatory environment leads to two general types of cannabis being produced in Canada, each with its own standards. These are commercial cannabis products that adhere to Good Production Practices (GPP) regulations and cannabis for research purposes that falls under Good Manufacturing Practices (GMP) standards. This difference creates a barrier to research.

To read the complete article, go to

Publication date:

Receive the daily newsletter in your email for free | Click here

Other news in this sector:

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber